Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis.

Takagi H, Kakizaki S, Sohara N, Sato K, Tsukioka G, Tago Y, Konaka K, Kabeya K, Kaneko M, Takayama H, Hashimoto Y, Yamada T, Takahashi H, Shimojo H, Nagamine T, Mori M.

Int J Vitam Nutr Res. 2003 Nov;73(6):411-5.

PMID:
14743544
2.

Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.

Tarao K, Fujiyama S, Ohkawa S, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Tanaka K.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9.

3.

Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.

Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J.

J Gastroenterol Hepatol. 2013 Feb;28(2):357-64. doi: 10.1111/jgh.12057.

PMID:
23190084
4.

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.

Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Arase Y, Murashima N, Chayama K, Kumada H.

J Gastroenterol Hepatol. 2001 Apr;16(4):406-15.

PMID:
11354279
5.

Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.

Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takanashi Y, Imada T.

Anticancer Res. 2006 May-Jun;26(3B):2221-6.

6.

Serum alanine aminotransferase levels and survival after hepatectomy in patients with hepatocellular carcinoma and hepatitis C virus-associated liver cirrhosis.

Tarao K, Rino Y, Takemiya S, Ohkawa S, Sugimasa Y, Miyakawa K, Tamai S, Masaki T, Hirokawa S, Kameda Y, Nagaoka T, Okamoto N, Kokubu S, Yoshida M, Kakita A.

Cancer Sci. 2003 Dec;94(12):1083-90.

7.

Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.

Rodríguez-Díaz JL, Rosas-Camargo V, Vega-Vega O, Morales-Espinosa D, Mendez-Reguera A, Martínez-Tlahuel JL, Gamboa-Domínguez A, Arrieta O.

Clin Oncol (R Coll Radiol). 2007 Apr;19(3):197-203. Epub 2007 Jan 18.

PMID:
17359907
8.

Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.

Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, Endo O, Yoshitsugu M, Watanabe N, Matsuzaki S.

Cancer. 2002 Mar 15;94(6):1787-95.

9.

Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.

Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G.

Cancer. 2001 Jul 1;92(1):126-35.

PMID:
11443618
10.

Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A.

Tarao K, Rino Y, Ohkawa S, Endo O, Miyakawa K, Tamai S, Hirokawa S, Masaki T, Nagaoka T, Okamoto N, Tanaka K, Tarao N.

Intervirology. 2004;47(2):65-71.

PMID:
15192269
11.

Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis.

Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, Aoki H, Imada T, Shindo K, Okamoto N, Totsuka S.

Cancer. 1999 Aug 15;86(4):589-95.

PMID:
10440686
12.

Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.

Scand J Gastroenterol. 2008;43(7):849-56. doi: 10.1080/00365520801935459.

PMID:
18584524
13.

Close association between high serum ALT and more rapid recurrence of hepatocellular carcinoma in hepatectomized patients with HCV-associated liver cirrhosis and hepatocellular carcinoma.

Tarao K, Rino Y, Takemiya S, Tamai S, Ohkawa S, Sugimasa Y, Miyakawa K, Morinaga S, Yoshida M, Shibuya A, Kokubu S, Kakita A, Endo O.

Intervirology. 2000;43(1):20-6.

PMID:
10773734
14.

A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis.

Tanaka K, Sakai H, Hashizume M, Hirohata T.

Jpn J Cancer Res. 1998 Dec;89(12):1241-50.

PMID:
10081484
15.

[Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].

Petry W, Heintges T, Hensel F, Erhardt A, Wenning M, Niederau C, Häussinger D.

Z Gastroenterol. 1997 Dec;35(12):1059-67. German.

PMID:
9487638
16.

High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.

Miyakawa K, Tarao K, Ohshige K, Morinaga S, Ohkawa S, Okamoto N, Shibuya A, Adachi S, Miura Y, Fujiyama S, Miyase S, Tomita K.

Scand J Gastroenterol. 2009;44(11):1340-8. doi: 10.3109/00365520903222681.

PMID:
19891585
18.

Oxidative-inflammatory damage in cirrhosis: effect of vitamin E and a fermented papaya preparation.

Marotta F, Yoshida C, Barreto R, Naito Y, Packer L.

J Gastroenterol Hepatol. 2007 May;22(5):697-703.

PMID:
17444858
19.
20.

Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C.

Goshima S, Kanematsu M, Kondo H, Watanabe H, Noda Y, Fujita H, Bae KT.

Eur J Radiol. 2015 May;84(5):811-5. doi: 10.1016/j.ejrad.2015.01.009. Epub 2015 Jan 22.

PMID:
25650331

Supplemental Content

Support Center